A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2015
At a glance
- Drugs CCX 140 (Primary)
- Indications Diabetic nephropathies; Proteinuria; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors ChemoCentryx
- 10 Jun 2017 Biomarkers information updated
- 08 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2013 Planned end date changed from 1 Feb 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.